Malgieri, Maria C

Minaris Regenerative Medicine, a global Contract Development and Manufacturing Organization (CDMO) based in Allendale, NJ, specializes in providing high-value clinical and commercial manufacturing services for cell and gene therapy products. With over 20 years of experience, they offer development solutions, cutting-edge technologies, and state-of-the-art facilities to support the creation of future cell therapy miracles. Through their expert team and global facilities in North America, Europe, and Asia, Minaris Regenerative Medicine has successfully served over 180 clients with exceptional quality and reliability. Their commitment to excellence, innovative solutions, and collaborative approach make them a valuable partner in advancing the boundaries of medicine to benefit patients in need.Generated from the website

The Medical Research Network (MRN) is a private clinical research site established in 1997 by Dr. Michael R. Liebowitz, specializing in psychiatric, neurological, and chronic pain disorders. Located in the Upper East Side of New York City, MRN focuses on discovering the treatments of tomorrow today through its current studies on various mental health conditions. MRN offers research opportunities for individuals dealing with disorders such as depression, social anxiety, post-traumatic stress disorder, borderline personality disorder, and attention deficit hyperactivity disorder. By participating in these studies, individuals can contribute to groundbreaking advancements in mental health treatment. Generated from the website

ENB Therapeutics is a pioneering biopharmaceutical company based in New York, NY, dedicated to overcoming immunotherapy resistance in cancer treatment. Their innovative approach targets the tumor microenvironment, utilizing two unique mechanisms to empower the body's immune system in effectively combating drug-resistant cancers. By developing small molecules that turn off a common switch activating pro-cancer components of the tumor microenvironment, ENB Therapeutics aims to transform "cold" tumors into "hot" tumors, enabling immune cells to infiltrate and kill cancer cells. Additionally, their therapies promote the formation of intratumoral tertiary lymphoid organs (TLOs), which act as antibody factories and induce long-lasting anti-cancer immunity. With demonstrated preclinical efficacy in various cancer types, including melanoma, glioblastoma, and ovarian cancer, ENB Therapeutics is at the forefront of a new era in cancer therapy.Generated from the website